^
Association details:
| Biomarker: | SF3B1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + mivebresib (ABBV 075) (BET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarker Modulation By Mivebresib (ABBV-075) +/– Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
Published date:
11/06/2019
Excerpt:
Biologic activity was observed particularly in patients treated with MIV-VEN who had SF3B1/U2AF1 or PTPN11 mutations.
DOI:
https://doi.org/10.1182/blood-2019-126854
Trial ID:
